{"id":129871,"date":"2021-02-05T09:00:12","date_gmt":"2021-02-05T08:00:12","guid":{"rendered":"https:\/\/medios.uchceu.es\/actualidad-ceu\/?p=129871"},"modified":"2023-05-30T10:24:49","modified_gmt":"2023-05-30T08:24:49","slug":"les-enjeux-de-la-pharmacovigilance-en-oncologie","status":"publish","type":"post","link":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/les-enjeux-de-la-pharmacovigilance-en-oncologie\/","title":{"rendered":"Les enjeux de la pharmacovigilance en oncologie"},"content":{"rendered":"<ul>\n<li><strong>Les traitements sp\u00e9cifiques pour chaque patient, avec des dosages personnalis\u00e9s, font l\u2019actualit\u00e9 dans la recherche contre le cancer, selon Vanesa Escudero, chercheuse de l\u2019Universit\u00e9 CEU UCH \u00e0 Elche.<\/strong><\/li>\n<li><strong>Gr\u00e2ce \u00e0 la pharmacovigilance en oncologie, on pourra ajuster les doses et identifier un pourcentage \u00e9lev\u00e9 de patients, chez qui, a priori, les sch\u00e9mas posologiques standards conduiraient \u00e0 une absence de r\u00e9ponse clinique.<\/strong><\/li>\n<\/ul>\n<p>Depuis 2005, <a href=\"https:\/\/www.uchceu.es\/directorio\/vanesa-escudero?_ga=2.14631860.260075482.1615194187-1882249699.1588245643&amp;_gac=1.83762276.1615365442.cj0kcqjwoaz3brdnarisaf1rfldkpueuar6gzbql7tdfwtmxos2zeugzhi8uijwurwc_tzm6z-rgnbuaaqz4ealw_wcb\" target=\"_blank\" rel=\"noopener\">Vanesa Escudero<\/a>\u00a0travaille dans la recherche sur la <a href=\"http:\/\/www.plataformadeoncologia.com\/webcms\/index.php?menu=176\" target=\"_blank\" rel=\"noopener\">Pharmacologie quantitative et Pharmacologie personnalis\u00e9e<\/a> , plus particuli\u00e8rement dans les domaines li\u00e9s \u00e0 la lutte contre le cancer tels que les sch\u00e9mas posologiques personnalis\u00e9s pour le traitement de chimioth\u00e9rapie classique, les m\u00e9dicaments \u00e0 petites mol\u00e9cules, les techniques de mod\u00e9lisation, la simulation pharmacocin\u00e9tique et la pharmacodynamique en oncologie.<\/p>\n<p>Bien qu\u2019elle soit aussi sp\u00e9cialis\u00e9e dans les traitements d\u2019immunoth\u00e9rapie du cancer, elle se consacre \u00e0 pr\u00e9sent aux enjeux de la pharmacovigilance en oncologie.\u00a0Cette professeure du d\u00e9partement de Soins infirmiers au CEU d\u2019Elche\u00a0est \u00e0 la t\u00eate de deux projets de recherche, financ\u00e9s par la Generalitat Valenciana. L\u2019un d\u2019entre eux a permis la mise en place d\u2019un syst\u00e8me de surveillance des traitements par imatinib, dasatinib et nilotinib dans la pratique clinique de routine pour augmenter l\u2019efficacit\u00e9 et r\u00e9duire la toxicit\u00e9 de ces th\u00e9rapies chez les patients h\u00e9mato-oncologiques.<\/p>\n<figure id=\"attachment_128470\" aria-describedby=\"caption-attachment-128470\" style=\"width: 2177px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-128470\" src=\"https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4745-scaled.jpg\" alt=\"\" width=\"2177\" height=\"2560\" srcset=\"https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4745-scaled.jpg 2177w, https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4745-255x300.jpg 255w, https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4745-1060x1247.jpg 1060w, https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4745-768x903.jpg 768w, https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4745-1306x1536.jpg 1306w, https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4745-1741x2048.jpg 1741w, https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4745-1020x1200.jpg 1020w, https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4745-150x176.jpg 150w, https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4745-300x353.jpg 300w, https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4745-696x819.jpg 696w, https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4745-1068x1256.jpg 1068w, https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4745-1920x2258.jpg 1920w, https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4745-357x420.jpg 357w\" sizes=\"auto, (max-width: 2177px) 100vw, 2177px\" \/><figcaption id=\"caption-attachment-128470\" class=\"wp-caption-text\">Dr. Vanesa Escudero, chercheuse du CEU en pharmacovigilance en oncologie<\/figcaption><\/figure>\n<p><strong>Dans le domaine de la lutte contre le cancer, le concept de <a href=\"https:\/\/www.cancer.gov\/espanol\/cancer\/tratamiento\/tipos\/pruebas-de-biomarcadores-tratamiento-cancer\" target=\"_blank\" rel=\"noopener\">M\u00e9decine de pr\u00e9cision en oncologie<\/a> \u00a0a \u00e9t\u00e9 mis en valeur. Que signifie ce terme\u00a0?\u00a0<\/strong><\/p>\n<p>Une des principales avanc\u00e9es dans le traitement et dans la recherche contre le cancer, est de pouvoir adapter le traitement en fonction de chaque patient, et pas seulement en fonction des caract\u00e9ristiques g\u00e9n\u00e9tiques de la tumeur mais aussi des caract\u00e9ristiques du patient qui peuvent agir sur les facteurs tels que le m\u00e9tabolisme ou l\u2019\u00e9limination des m\u00e9dicaments. C\u2019est dans ce contexte qu\u2019on entend parler de m\u00e9decine de pr\u00e9cision.<\/p>\n<p>La m\u00e9decine de pr\u00e9cision en oncologie a un objectif double\u00a0: elle permet aux patients de pouvoir b\u00e9n\u00e9ficier d\u2019un traitement sp\u00e9cifique \u00ab\u00a0guid\u00e9 ou dirig\u00e9\u00a0\u00bb selon le profil g\u00e9n\u00e9tique de sa tumeur. Elle permet aussi de personnaliser les doses administr\u00e9es afin de minimiser la toxicit\u00e9 et de maximiser l\u2019efficacit\u00e9 des traitements.<\/p>\n<p>Cet objectif de la personnalisation des doses en oncologie se fait gr\u00e2ce \u00e0 la pharmacovigilance th\u00e9rapeutique des m\u00e9dicaments, un outil fondamental pour la m\u00e9decine de pr\u00e9cision. Cet outil est le sujet de l\u2019\u00e9tude du groupe de recherche en pharmacie et nutrition de l\u2019Universit\u00e9 CEU Cardenal Herrera.<\/p>\n<p><strong>\u00c9tant donn\u00e9 votre exp\u00e9rience en analyse biologique et dans la surveillance des m\u00e9dicaments anticanc\u00e9reux et des antid\u00e9presseurs dans la pratique clinique, que signifie la personnalisation du traitement en oncologie\u00a0?<\/strong><\/p>\n<p>L\u2019\u00e9tude g\u00e9n\u00e9tique de la tumeur permet de \u201cconnaitre chaque tumeur de chaque patient de mani\u00e8re plus personnalis\u00e9e\u201d. Une fois l\u2019\u00e9tude g\u00e9n\u00e9tique effectu\u00e9e, on s\u00e9lectionne un traitement pharmacologique plus sp\u00e9cifique, plus b\u00e9n\u00e9fique pour le patient. Dans une approche conventionnelle, ces traitements oncologiques sont administr\u00e9s sous forme de dose fixe ou standard en fonction du poids ou de la surface corporelle du patient. Ces param\u00e8tres ne refl\u00e8tent souvent pas bien le m\u00e9tabolisme r\u00e9el du patient. En d\u2019autres termes, diff\u00e9rents individus recevant des doses similaires, peuvent souffrir de diff\u00e9rents niveaux de toxicit\u00e9 ou avoir besoin d\u2019une dose de m\u00e9dicament sup\u00e9rieure ou inf\u00e9rieure. Pour les professionnels de la sant\u00e9 charg\u00e9s des patients, r\u00e9ussir \u00e0 trouver un \u00e9quilibre entre toxicit\u00e9 et efficacit\u00e9 chez chaque patient est un r\u00e9el d\u00e9fi chaque jour.<\/p>\n<p>Gr\u00e2ce aux progr\u00e8s dans la m\u00e9decine de pr\u00e9cision, ces m\u00e9dicaments s\u00e9lectionn\u00e9s, seront contr\u00f4l\u00e9s pour ajuster leur sch\u00e9ma posologique de mani\u00e8re individualis\u00e9e, en tenant compte des facteurs inh\u00e9rents au patient (alimentation, autres m\u00e9dicaments, autres pathologies, facteurs pharmacocin\u00e9tiques individuels, etc.).<\/p>\n<p>En d\u2019autres termes, on r\u00e9alise un traitement \u201csur mesure\u201d pour chaque patient. Vous imaginez une boutique de chaussures qui vend une seule pointure pour tous les clients\u00a0?<\/p>\n<p>Il existe de nombreuses \u00e9tudes dans la litt\u00e9rature scientifique qui montrent l\u2019utilisation de cet outil dans la personnalisation de la posologie. Elles montrent que la personnalisation de la posologie d\u2019un m\u00e9dicament antin\u00e9oplasique, bas\u00e9e sur la pharmacovigilance, am\u00e9liore consid\u00e9rablement le nombre de r\u00e9ponses objectives, augmente le taux de survie sans r\u00e9cidive et r\u00e9duit la toxicit\u00e9.<\/p>\n<h3>Avantages des doses personnalis\u00e9es<\/h3>\n<p><strong>Comment se d\u00e9roule la personnalisation du traitement oncologique ?<\/strong><\/p>\n<p>Le processus pour le patient est simple. Pour pouvoir r\u00e9aliser la personnalisation de la dose de m\u00e9dicament, il faut disposer de certaines informations de l\u2019histoire clinique du patient. De plus, une fois la premi\u00e8re dose administr\u00e9e (par voie orale ou intraveineuse), on fera une s\u00e9rie de prises de sang qui nous permettra d\u2019en savoir plus sur le comportement du m\u00e9dicament sur chaque patient. Avec toutes ces donn\u00e9es, on estimera les param\u00e8tres pharmacocin\u00e9tiques individuels \u00e0 partir desquels on ajustera la dose si n\u00e9cessaire.<\/p>\n<p><strong>Quels b\u00e9n\u00e9fices la personnalisation de la posologie apporte-t-elle au patient ?\u00a0<\/strong><\/p>\n<p>La surveillance th\u00e9rapeutique des m\u00e9dicaments en oncologie apportera au patient de nombreux b\u00e9n\u00e9fices. Connaitre la quantit\u00e9 de m\u00e9dicament dans le sang apr\u00e8s l\u2019administration du traitement permettra d\u2019ajuster les doses et d\u2019identifier les patients qui ne r\u00e9pondraient au traitement en cas de \u00ab\u00a0sous-dosage\u00a0\u00bb et les patients sur qui les effets secondaires pourraient limiter leur traitement en cas de \u00ab\u00a0surdosage\u00a0\u00bb. \u00ab\u00a0La pr\u00e9vention des effets secondaires ind\u00e9sirables am\u00e9liorera la s\u00e9curit\u00e9 du patient et par cons\u00e9quent sa qualit\u00e9 de vie\u00a0\u00bb.<\/p>\n<figure id=\"attachment_128509\" aria-describedby=\"caption-attachment-128509\" style=\"width: 2152px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-128509\" src=\"https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/Vanesa-Escudero-dirige-dos-proyectos-de-investigacion-oncologica-1-scaled.jpg\" alt=\"\" width=\"2152\" height=\"2560\" srcset=\"https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/Vanesa-Escudero-dirige-dos-proyectos-de-investigacion-oncologica-1-scaled.jpg 2152w, https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/Vanesa-Escudero-dirige-dos-proyectos-de-investigacion-oncologica-1-252x300.jpg 252w, https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/Vanesa-Escudero-dirige-dos-proyectos-de-investigacion-oncologica-1-1060x1261.jpg 1060w, https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/Vanesa-Escudero-dirige-dos-proyectos-de-investigacion-oncologica-1-768x913.jpg 768w, https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/Vanesa-Escudero-dirige-dos-proyectos-de-investigacion-oncologica-1-1291x1536.jpg 1291w, https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/Vanesa-Escudero-dirige-dos-proyectos-de-investigacion-oncologica-1-1722x2048.jpg 1722w, https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/Vanesa-Escudero-dirige-dos-proyectos-de-investigacion-oncologica-1-1009x1200.jpg 1009w, https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/Vanesa-Escudero-dirige-dos-proyectos-de-investigacion-oncologica-1-150x178.jpg 150w, https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/Vanesa-Escudero-dirige-dos-proyectos-de-investigacion-oncologica-1-300x357.jpg 300w, https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/Vanesa-Escudero-dirige-dos-proyectos-de-investigacion-oncologica-1-696x828.jpg 696w, https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/Vanesa-Escudero-dirige-dos-proyectos-de-investigacion-oncologica-1-1068x1270.jpg 1068w, https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/Vanesa-Escudero-dirige-dos-proyectos-de-investigacion-oncologica-1-1920x2284.jpg 1920w, https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/Vanesa-Escudero-dirige-dos-proyectos-de-investigacion-oncologica-1-353x420.jpg 353w\" sizes=\"auto, (max-width: 2152px) 100vw, 2152px\" \/><figcaption id=\"caption-attachment-128509\" class=\"wp-caption-text\">Vanesa Escudero \u00e0 la t\u00eate de deux projets de recherche contre le cancer<\/figcaption><\/figure>\n<h3>D\u00e9fis actuels<\/h3>\n<p><strong>Quels sont les d\u00e9fis actuels dans la pharmacovigilance en oncologie ?\u00a0<\/strong><\/p>\n<p>La surveillance th\u00e9rapeutique des m\u00e9dicaments est un d\u00e9fi sur lequel travailler afin de couvrir tous les traitements contre le cancer. Int\u00e9grer cet outil dans la pratique clinique de routine profite aux patients et signifie \u00e9galement que vous menez des recherches de pointe. De plus, \u201cla mise en place de cet outil doit \u00eatre accompagn\u00e9e de projets de recherche qui permettent de cr\u00e9er et de partager des informations, afin de pouvoir approfondir nos connaissances dans ce domaine et fournir de meilleurs soins au patient atteint d\u2019un cancer\u00a0. \u00bb<\/p>\n<p><strong>Sur quel projet travaille le <a href=\"https:\/\/www.uchceu.es\/grupos-lineas-investigacion\/grupo-de-investigacion-en-farmacia-y-nutricion-clinica-clinicpharma?_ga=2.221144475.260075482.1615194187-1882249699.1588245643&amp;_gac=1.191698136.1615365442.Cj0KCQjwoaz3BRDnARIsAF1RfLdKPueUAr6gzBQL7TdfWTMxos2zEuGzhI8uIjWURWc_tZm6Z-rgNBUaAqz4EALw_wcB\" target=\"_blank\" rel=\"noopener\">Groupe de Recherche en Pharmacie et Nutrition Clinique du CEU<\/a> , dont vous \u00eates la chercheuse principale\u00a0?<\/strong><\/p>\n<p>Nous travaillons sur le d\u00e9veloppement de nouvelles techniques d\u2019analyse biologique pour la quantification de m\u00e9dicaments chez les patients atteints d\u2019un cancer. Et aussi sur le d\u00e9veloppement de mod\u00e8les pharmacocin\u00e9tiques n\u00e9cessaires pour la personnalisation de la th\u00e9rapie. Actuellement, le groupe <a href=\"https:\/\/medios.uchceu.es\/actualidad-ceu\/la-ceu-uch-y-la-fundacion-fisabio-pondran-en-marcha-un-grupo-mixto-de-investigacion-en-farmacia-y-nutricion-clinica\/\" target=\"_blank\" rel=\"noopener\">\u00a0collabore activement<\/a>\u00a0dans les recherches men\u00e9es par <a href=\"http:\/\/fisabio.san.gva.es\/documents\/10157\/7d367c40-16b0-404b-8438-eb273853b6a1\" target=\"_blank\" rel=\"noopener\">l&rsquo;Hospital General Universitario de Elche<\/a>, l\u2019\u00a0Hospital Vega Baja,<a href=\"http:\/\/fisabio.san.gva.es\/hospital-general-universitario-de-alicante1\" target=\"_blank\" rel=\"noopener\"> l\u2019\u00a0Hospital General Universitario de Alicante\u00a0<\/a>et <a href=\"https:\/\/www.quironsalud.es\/torrevieja\" target=\"_blank\" rel=\"noopener\">l\u2019\u00a0Hospital Quironsalud de Torrevieja.<\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Les traitements sp\u00e9cifiques pour chaque patient, avec des dosages personnalis\u00e9s, font l\u2019actualit\u00e9 dans la recherche contre le cancer, selon Vanesa Escudero, chercheuse de l\u2019Universit\u00e9 CEU UCH \u00e0 Elche. Gr\u00e2ce \u00e0 la pharmacovigilance en oncologie, on pourra ajuster les doses et identifier un pourcentage \u00e9lev\u00e9 de patients, chez qui, a priori, les sch\u00e9mas posologiques standards conduiraient [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":128466,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-129871","post","type-post","status-publish","format-standard","has-post-thumbnail","category-sin-categorizar"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Les enjeux de la pharmacovigilance en oncologie<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/les-enjeux-de-la-pharmacovigilance-en-oncologie\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Les enjeux de la pharmacovigilance en oncologie\" \/>\n<meta property=\"og:description\" content=\"Les traitements sp\u00e9cifiques pour chaque patient, avec des dosages personnalis\u00e9s, font l\u2019actualit\u00e9 dans la recherche contre le cancer, selon Vanesa Escudero, chercheuse de l\u2019Universit\u00e9 CEU UCH \u00e0 Elche. Gr\u00e2ce \u00e0 la pharmacovigilance en oncologie, on pourra ajuster les doses et identifier un pourcentage \u00e9lev\u00e9 de patients, chez qui, a priori, les sch\u00e9mas posologiques standards conduiraient [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/les-enjeux-de-la-pharmacovigilance-en-oncologie\/\" \/>\n<meta property=\"og:site_name\" content=\"Actualidad CEU\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/UCHCEU\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-05T08:00:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-30T08:24:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Teresa Soriano\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@uchceu\" \/>\n<meta name=\"twitter:site\" content=\"@uchceu\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Teresa Soriano\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/les-enjeux-de-la-pharmacovigilance-en-oncologie\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/les-enjeux-de-la-pharmacovigilance-en-oncologie\\\/\"},\"author\":{\"name\":\"Teresa Soriano\",\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/#\\\/schema\\\/person\\\/75888c87eee5b0fb7727a035f357b0ae\"},\"headline\":\"Les enjeux de la pharmacovigilance en oncologie\",\"datePublished\":\"2021-02-05T08:00:12+00:00\",\"dateModified\":\"2023-05-30T08:24:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/les-enjeux-de-la-pharmacovigilance-en-oncologie\\\/\"},\"wordCount\":1244,\"publisher\":{\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/les-enjeux-de-la-pharmacovigilance-en-oncologie\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2021\\\/02\\\/IMG_4724-scaled.jpg\",\"articleSection\":[\"Sin categorizar\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/les-enjeux-de-la-pharmacovigilance-en-oncologie\\\/\",\"url\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/les-enjeux-de-la-pharmacovigilance-en-oncologie\\\/\",\"name\":\"Les enjeux de la pharmacovigilance en oncologie\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/les-enjeux-de-la-pharmacovigilance-en-oncologie\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/les-enjeux-de-la-pharmacovigilance-en-oncologie\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2021\\\/02\\\/IMG_4724-scaled.jpg\",\"datePublished\":\"2021-02-05T08:00:12+00:00\",\"dateModified\":\"2023-05-30T08:24:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/les-enjeux-de-la-pharmacovigilance-en-oncologie\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/les-enjeux-de-la-pharmacovigilance-en-oncologie\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/les-enjeux-de-la-pharmacovigilance-en-oncologie\\\/#primaryimage\",\"url\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2021\\\/02\\\/IMG_4724-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2021\\\/02\\\/IMG_4724-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/les-enjeux-de-la-pharmacovigilance-en-oncologie\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Les enjeux de la pharmacovigilance en oncologie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/\",\"name\":\"Actualidad CEU\",\"description\":\"El peri\u00f3dico de la Universidad CEU Cardenal Herrera\",\"publisher\":{\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/#organization\"},\"alternateName\":\"AC\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/#organization\",\"name\":\"Universidad CEU Cardenal Herrera\",\"url\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2018\\\/11\\\/logotipo-ceu-uch-gris.png\",\"contentUrl\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2018\\\/11\\\/logotipo-ceu-uch-gris.png\",\"width\":540,\"height\":140,\"caption\":\"Universidad CEU Cardenal Herrera\"},\"image\":{\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/UCHCEU\",\"https:\\\/\\\/x.com\\\/uchceu\",\"https:\\\/\\\/www.instagram.com\\\/uchceu_universidad\",\"https:\\\/\\\/www.linkedin.com\\\/school\\\/497316\",\"https:\\\/\\\/www.youtube.com\\\/ceuvalencia\",\"https:\\\/\\\/www.tiktok.com\\\/@uchceu_universidad\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/#\\\/schema\\\/person\\\/75888c87eee5b0fb7727a035f357b0ae\",\"name\":\"Teresa Soriano\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5e836d6083a5d74f4a0790f9b1204011e05451924fdec99e71bebe26a93be367?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5e836d6083a5d74f4a0790f9b1204011e05451924fdec99e71bebe26a93be367?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5e836d6083a5d74f4a0790f9b1204011e05451924fdec99e71bebe26a93be367?s=96&d=mm&r=g\",\"caption\":\"Teresa Soriano\"},\"url\":\"https:\\\/\\\/medios.uchceu.es\\\/actualidad-ceu\\\/fr\\\/author\\\/tsoriano\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Les enjeux de la pharmacovigilance en oncologie","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/les-enjeux-de-la-pharmacovigilance-en-oncologie\/","og_locale":"fr_FR","og_type":"article","og_title":"Les enjeux de la pharmacovigilance en oncologie","og_description":"Les traitements sp\u00e9cifiques pour chaque patient, avec des dosages personnalis\u00e9s, font l\u2019actualit\u00e9 dans la recherche contre le cancer, selon Vanesa Escudero, chercheuse de l\u2019Universit\u00e9 CEU UCH \u00e0 Elche. Gr\u00e2ce \u00e0 la pharmacovigilance en oncologie, on pourra ajuster les doses et identifier un pourcentage \u00e9lev\u00e9 de patients, chez qui, a priori, les sch\u00e9mas posologiques standards conduiraient [&hellip;]","og_url":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/les-enjeux-de-la-pharmacovigilance-en-oncologie\/","og_site_name":"Actualidad CEU","article_publisher":"https:\/\/www.facebook.com\/UCHCEU","article_published_time":"2021-02-05T08:00:12+00:00","article_modified_time":"2023-05-30T08:24:49+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-scaled.jpg","type":"image\/jpeg"}],"author":"Teresa Soriano","twitter_card":"summary_large_image","twitter_creator":"@uchceu","twitter_site":"@uchceu","twitter_misc":{"\u00c9crit par":"Teresa Soriano","Dur\u00e9e de lecture estim\u00e9e":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/les-enjeux-de-la-pharmacovigilance-en-oncologie\/#article","isPartOf":{"@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/les-enjeux-de-la-pharmacovigilance-en-oncologie\/"},"author":{"name":"Teresa Soriano","@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/#\/schema\/person\/75888c87eee5b0fb7727a035f357b0ae"},"headline":"Les enjeux de la pharmacovigilance en oncologie","datePublished":"2021-02-05T08:00:12+00:00","dateModified":"2023-05-30T08:24:49+00:00","mainEntityOfPage":{"@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/les-enjeux-de-la-pharmacovigilance-en-oncologie\/"},"wordCount":1244,"publisher":{"@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/#organization"},"image":{"@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/les-enjeux-de-la-pharmacovigilance-en-oncologie\/#primaryimage"},"thumbnailUrl":"https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-scaled.jpg","articleSection":["Sin categorizar"],"inLanguage":"fr-FR"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/les-enjeux-de-la-pharmacovigilance-en-oncologie\/","url":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/les-enjeux-de-la-pharmacovigilance-en-oncologie\/","name":"Les enjeux de la pharmacovigilance en oncologie","isPartOf":{"@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/les-enjeux-de-la-pharmacovigilance-en-oncologie\/#primaryimage"},"image":{"@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/les-enjeux-de-la-pharmacovigilance-en-oncologie\/#primaryimage"},"thumbnailUrl":"https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-scaled.jpg","datePublished":"2021-02-05T08:00:12+00:00","dateModified":"2023-05-30T08:24:49+00:00","breadcrumb":{"@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/les-enjeux-de-la-pharmacovigilance-en-oncologie\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/les-enjeux-de-la-pharmacovigilance-en-oncologie\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/les-enjeux-de-la-pharmacovigilance-en-oncologie\/#primaryimage","url":"https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-scaled.jpg","contentUrl":"https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/les-enjeux-de-la-pharmacovigilance-en-oncologie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/"},{"@type":"ListItem","position":2,"name":"Les enjeux de la pharmacovigilance en oncologie"}]},{"@type":"WebSite","@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/#website","url":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/","name":"Actualidad CEU","description":"El peri\u00f3dico de la Universidad CEU Cardenal Herrera","publisher":{"@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/#organization"},"alternateName":"AC","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/#organization","name":"Universidad CEU Cardenal Herrera","url":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2018\/11\/logotipo-ceu-uch-gris.png","contentUrl":"https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2018\/11\/logotipo-ceu-uch-gris.png","width":540,"height":140,"caption":"Universidad CEU Cardenal Herrera"},"image":{"@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/UCHCEU","https:\/\/x.com\/uchceu","https:\/\/www.instagram.com\/uchceu_universidad","https:\/\/www.linkedin.com\/school\/497316","https:\/\/www.youtube.com\/ceuvalencia","https:\/\/www.tiktok.com\/@uchceu_universidad"]},{"@type":"Person","@id":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/#\/schema\/person\/75888c87eee5b0fb7727a035f357b0ae","name":"Teresa Soriano","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/5e836d6083a5d74f4a0790f9b1204011e05451924fdec99e71bebe26a93be367?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5e836d6083a5d74f4a0790f9b1204011e05451924fdec99e71bebe26a93be367?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5e836d6083a5d74f4a0790f9b1204011e05451924fdec99e71bebe26a93be367?s=96&d=mm&r=g","caption":"Teresa Soriano"},"url":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/author\/tsoriano\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-scaled.jpg",2560,1707,false],"thumbnail":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-150x150.jpg",150,150,true],"medium":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-300x200.jpg",300,200,true],"medium_large":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-768x512.jpg",696,464,true],"large":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-1060x707.jpg",696,464,true],"listado":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-310x174.jpg",310,174,true],"nuevaweb":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-280x280.jpg",280,280,true],"destacadablogs":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-580x280.jpg",580,280,true],"1536x1536":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-1536x1024.jpg",1536,1024,true],"2048x2048":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-2048x1365.jpg",2048,1365,true],"complete_open_graph":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-1200x800.jpg",1200,800,true],"td_150x0":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-150x100.jpg",150,100,true],"td_218x150":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-218x150.jpg",218,150,true],"td_300x0":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-300x200.jpg",300,200,true],"td_324x400":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-324x400.jpg",324,400,true],"td_485x360":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-485x360.jpg",485,360,true],"td_696x0":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-696x464.jpg",696,464,true],"td_1068x0":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-1068x712.jpg",1068,712,true],"td_1920x0":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-1920x1280.jpg",1920,1280,true],"td_0x420":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-630x420.jpg",630,420,true],"td_80x60":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-80x60.jpg",80,60,true],"td_100x70":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-100x70.jpg",100,70,true],"td_265x198":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-265x198.jpg",265,198,true],"td_324x160":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-324x160.jpg",324,160,true],"td_324x235":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-324x235.jpg",324,235,true],"td_356x220":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-356x220.jpg",356,220,true],"td_356x364":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-356x364.jpg",356,364,true],"td_533x261":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-533x261.jpg",533,261,true],"td_534x462":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-534x462.jpg",534,462,true],"td_696x385":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-696x385.jpg",696,385,true],"td_741x486":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-741x486.jpg",741,486,true],"td_1068x580":["https:\/\/medios.uchceu.es\/actualidad-ceu\/wp-content\/uploads\/sites\/2\/2021\/02\/IMG_4724-1068x580.jpg",1068,580,true]},"uagb_author_info":{"display_name":"Teresa Soriano","author_link":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/author\/tsoriano\/"},"uagb_comment_info":0,"uagb_excerpt":"Les traitements sp\u00e9cifiques pour chaque patient, avec des dosages personnalis\u00e9s, font l\u2019actualit\u00e9 dans la recherche contre le cancer, selon Vanesa Escudero, chercheuse de l\u2019Universit\u00e9 CEU UCH \u00e0 Elche. Gr\u00e2ce \u00e0 la pharmacovigilance en oncologie, on pourra ajuster les doses et identifier un pourcentage \u00e9lev\u00e9 de patients, chez qui, a priori, les sch\u00e9mas posologiques standards conduiraient\u2026","_links":{"self":[{"href":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/wp-json\/wp\/v2\/posts\/129871","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/wp-json\/wp\/v2\/comments?post=129871"}],"version-history":[{"count":2,"href":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/wp-json\/wp\/v2\/posts\/129871\/revisions"}],"predecessor-version":[{"id":161479,"href":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/wp-json\/wp\/v2\/posts\/129871\/revisions\/161479"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/wp-json\/wp\/v2\/media\/128466"}],"wp:attachment":[{"href":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/wp-json\/wp\/v2\/media?parent=129871"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/wp-json\/wp\/v2\/categories?post=129871"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medios.uchceu.es\/actualidad-ceu\/fr\/wp-json\/wp\/v2\/tags?post=129871"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}